Last reviewed · How we verify

Combination (Bivalent) BNT162b2 and BNT162b2 OMI (combination-bivalent-bnt162b2-and-bnt162b2-omi)

Pfizer · FDA-approved approved Quality 44/100

Combination (Bivalent) BNT162b2 and BNT162b2 OMI (generic name: combination-bivalent-bnt162b2-and-bnt162b2-omi) is a vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of COVID-19 in individuals 12 years of age and older, Prevention of COVID-19 in individuals 5 years of age and older.

Pfizer's combination-bivalent-bnt162b2-and-bnt162b2-omi is a marketed COVID-19 vaccine developed by Pfizer Inc. It works by targeting the SARS-CoV-2 virus. The vaccine is indicated for individuals 12 years of age and older for prevention of COVID-19, and for individuals 5 years of age and older. This vaccine is clinically differentiated from others due to its combination of two bivalent components. It has achieved significant commercial success, generating $63.6B in revenue. There are no pipeline developments mentioned.

At a glance

Generic namecombination-bivalent-bnt162b2-and-bnt162b2-omi
SponsorPfizer
Drug classvaccine
TargetSARS-CoV-2 virus
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combination (Bivalent) BNT162b2 and BNT162b2 OMI

What is Combination (Bivalent) BNT162b2 and BNT162b2 OMI?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI (combination-bivalent-bnt162b2-and-bnt162b2-omi) is a vaccine drug developed by Pfizer, indicated for Prevention of COVID-19 in individuals 12 years of age and older, Prevention of COVID-19 in individuals 5 years of age and older.

What is Combination (Bivalent) BNT162b2 and BNT162b2 OMI used for?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI is indicated for Prevention of COVID-19 in individuals 12 years of age and older, Prevention of COVID-19 in individuals 5 years of age and older.

Who makes Combination (Bivalent) BNT162b2 and BNT162b2 OMI?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Combination (Bivalent) BNT162b2 and BNT162b2 OMI?

combination-bivalent-bnt162b2-and-bnt162b2-omi is the generic (nonproprietary) name of Combination (Bivalent) BNT162b2 and BNT162b2 OMI.

What drug class is Combination (Bivalent) BNT162b2 and BNT162b2 OMI in?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Combination (Bivalent) BNT162b2 and BNT162b2 OMI in?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI is FDA-approved (marketed).

What are the side effects of Combination (Bivalent) BNT162b2 and BNT162b2 OMI?

Common side effects of Combination (Bivalent) BNT162b2 and BNT162b2 OMI include Injection site pain, Fatigue, Headache, Pyrexia, Myalgia, Chills.

What does Combination (Bivalent) BNT162b2 and BNT162b2 OMI target?

Combination (Bivalent) BNT162b2 and BNT162b2 OMI targets SARS-CoV-2 virus and is a vaccine.

Related